PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.
Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...
Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
The biotech start-up Cure51 is working on the first global molecular database of exceptional survivors of cancer - Copyright AFP JUAN MABROMATA The biotech start-up ...
This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results